Choi, Wonseok Cho, Hyeyoun Jang, Hwijin Park, Hyewon Youn, Inchan Han, Sungmin Key, Jaehong 2025-11-24T09:35:58Z 2025-11-24T09:35:58Z 2025-11-21 2025-11 1177-8881 https://pubs.kist.re.kr/handle/201004/153638 Background: Pulmonary thromboembolism, a pathological condition characterized by the occlusion of pulmonary vasculature by free-circulating thrombus, constitutes the third leading cause of cardiovascular-related mortality. Among conventional therapeutic approaches to manage the disease, systemic intravenous thrombolysis is hindered by inherent pharmacokinetic and pharmacodynamic limitations, including a short biological half-life, high requisite dosages, and an increased risk of hemorrhagic transformation. Given the critical need for prompt pulmonary reperfusion, this study introduces a dual-targeted therapeutic strategy employing fucoidan-functionalized, thrombolytic discoidal polymeric microparticles. This dual-targeted approach leverages the physicochemical properties of disc-shaped particles, which exhibit shape-dependent accumulation in the lungs, together with the biological binding affinity provided by the marine-derived component, fucoidan. Methods: A top-down lithographic fabrication technique was employed to synthesize discoidal microparticle systems for physicochemical targeting to the pulmonary vasculature, providing precise control over the system’s geometry and uniform drug encapsulation efficiency. Furthermore, a PLGA polymeric matrix was positively modified to incorporate fucoidan onto its matrix surface, which is a sulfated polysaccharide with high-affinity interactions for P-selectin expressed on activated platelets in the nanomolar range. In vitro and in vivo thrombolysis assays were conducted to assess the therapeutic efficacy of microparticles. Results: The proposed discoidal systems coupled with the fucoidan showed rapid accumulation due to their shape and selective interaction with activated platelets. Approximately 50% of the injected microparticles exhibited preferential accumulation within 15 minutes post-injection, and a significant portion remained over assay times. The fucoidan functionalization enhanced the targeting potential, yielding a 4.65- and 1.48-fold increase under static and dynamic flow assays, respectively (all p< 0.01). Although dramatic dissolution was not achieved using the proposed system in comparison with rtPA, alongside in vitro and in vivo investigations, the systems exhibited a more prolonged and dose-dependent lytic potential. Conclusion: The proposed systems may offer an alternative to conventional systemic thrombolysis coupled with adjunctive pharmacological interventions. English Dove Medical Press Ltd A Dual-Targeted Therapy with Fucoidan-Functionalized Thrombolytic Discoidal Microparticles for Pulmonary Thromboembolism Article 10.2147/dddt.s527596 1 Drug Design, Development and Therapy, v.19, pp.10281 - 10297 Drug Design, Development and Therapy 19 10281 10297 Y scie scopus 001651913000001 Chemistry, Medicinal Pharmacology & Pharmacy Pharmacology & Pharmacy Article TISSUE-PLASMINOGEN ACTIVATOR DRUG-DELIVERY SYSTEM P-SELECTIN NANOPARTICLES EMBOLISM MICROBUBBLES CANCER PLGA SIZE discoidal polymeric particles fucoidan drug delivery system pulmonary thromboembolism